MORGANTOWN, W.Va. — Mylan Pharmaceuticals has received a green light to acquire a Swedish generic drug maker.
According to national reports, the European Commission has approved Mylan’s 7.2 billion dollar proposal for Meda.
The commission noted the acquisition is dependent upon Mylan and Meda getting rid of businesses in Austria, Belgium, France, Luxembourg, Ireland, Italy, Norway, Portugal, Spain and the UK.
That condition was put in place to avoid a lack of competition for customers in those areas.